These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 34779713)

  • 1. Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination.
    Iketani S; Liu L; Nair MS; Chandrashekar A; Mohri H; Wang M; Barouch DH; Huang Y; Ho DD
    Emerg Microbes Infect; 2021 Dec; 10(1):2220-2222. PubMed ID: 34779713
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunogenicity Following Administration of BNT162b2 and Ad26.COV2.S COVID-19 Vaccines in the Pregnant Population during the Third Trimester.
    Citu IM; Citu C; Gorun F; Sas I; Tomescu L; Neamtu R; Motoc A; Gorun OM; Burlea B; Bratosin F; Malita D
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine protection against the SARS-CoV-2 Omicron variant in macaques.
    Chandrashekar A; Yu J; McMahan K; Jacob-Dolan C; Liu J; He X; Hope D; Anioke T; Barrett J; Chung B; Hachmann NP; Lifton M; Miller J; Powers O; Sciacca M; Sellers D; Siamatu M; Surve N; VanWyk H; Wan H; Wu C; Pessaint L; Valentin D; Van Ry A; Muench J; Boursiquot M; Cook A; Velasco J; Teow E; Boon ACM; Suthar MS; Jain N; Martinot AJ; Lewis MG; Andersen H; Barouch DH
    Cell; 2022 Apr; 185(9):1549-1555.e11. PubMed ID: 35427477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID-19 vaccine in haemato-oncological patients with no antibody response.
    Reimann P; Ulmer H; Mutschlechner B; Benda M; Severgnini L; Volgger A; Lang T; Atzl M; Huynh M; Gasser K; Grabher C; Mink S; Fraunberger P; Petrausch U; Hartmann B; Winder T
    Br J Haematol; 2022 Feb; 196(3):577-584. PubMed ID: 34872162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.
    Alter G; Yu J; Liu J; Chandrashekar A; Borducchi EN; Tostanoski LH; McMahan K; Jacob-Dolan C; Martinez DR; Chang A; Anioke T; Lifton M; Nkolola J; Stephenson KE; Atyeo C; Shin S; Fields P; Kaplan I; Robins H; Amanat F; Krammer F; Baric RS; Le Gars M; Sadoff J; de Groot AM; Heerwegh D; Struyf F; Douoguih M; van Hoof J; Schuitemaker H; Barouch DH
    Nature; 2021 Aug; 596(7871):268-272. PubMed ID: 34107529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers.
    Brunner WM; Freilich D; Victory J; Krupa N; Scribani MB; Jenkins P; Lasher EG; Fink A; Shah A; Cross P; Bush V; Peek LJ; Pestano GA; Gadomski AM
    Int J Infect Dis; 2022 Oct; 123():183-191. PubMed ID: 36044963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques.
    Yu J; Tostanoski LH; Mercado NB; McMahan K; Liu J; Jacob-Dolan C; Chandrashekar A; Atyeo C; Martinez DR; Anioke T; Bondzie EA; Chang A; Gardner S; Giffin VM; Hope DL; Nampanya F; Nkolola J; Patel S; Sanborn O; Sellers D; Wan H; Hayes T; Bauer K; Pessaint L; Valentin D; Flinchbaugh Z; Brown R; Cook A; Bueno-Wilkerson D; Teow E; Andersen H; Lewis MG; Martinot AJ; Baric RS; Alter G; Wegmann F; Zahn R; Schuitemaker H; Barouch DH
    Nature; 2021 Aug; 596(7872):423-427. PubMed ID: 34161961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response.
    Mileto D; Fenizia C; Cutrera M; Gagliardi G; Gigantiello A; De Silvestri A; Rizzo A; Mancon A; Bianchi M; De Poli F; Cuomo M; Burgo I; Longo M; Rimoldi SG; Pagani C; Grosso S; Micheli V; Rizzardini G; Grande R; Biasin M; Gismondo MR; Lombardi A
    Emerg Microbes Infect; 2021 Dec; 10(1):2235-2243. PubMed ID: 34749573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
    Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Geers D; Schmitz KS; Garcia Garrido HM; Koopmans MPG; Dalm VASH; Kootstra NA; Huckriede ALW; Lafeber M; van Baarle D; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM;
    N Engl J Med; 2022 Mar; 386(10):951-963. PubMed ID: 35045226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques.
    Roozendaal R; Solforosi L; Stieh DJ; Serroyen J; Straetemans R; Dari A; Boulton M; Wegmann F; Rosendahl Huber SK; van der Lubbe JEM; Hendriks J; Le Gars M; Dekking L; Czapska-Casey DN; Guimera N; Janssen S; Tete S; Chandrashekar A; Mercado NB; Yu J; Koudstaal W; Perez-Ruixo JJ; Sadoff J; Barouch DH; Schuitemaker H; Zahn R
    Nat Commun; 2021 Oct; 12(1):5877. PubMed ID: 34620860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durability of Heterologous and Homologous COVID-19 Vaccine Boosts.
    Tan CS; Collier AY; Yu J; Liu J; Chandrashekar A; McMahan K; Jacob-Dolan C; He X; Roy V; Hauser BM; Munt JE; Mallory ML; Mattocks M; Powers JM; Meganck RM; Rowe M; Hemond R; Bondzie EA; Jaegle KH; Baric RS; Schmidt AG; Alter G; Le Gars M; Sadoff J; Barouch DH
    JAMA Netw Open; 2022 Aug; 5(8):e2226335. PubMed ID: 35947380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?
    Terpos E; Trougakos IP; Karalis V; Ntanasis-Stathopoulos I; Sklirou AD; Bagratuni T; Papanagnou ED; Patseas D; Gumeni S; Malandrakis P; Korompoki E; Dimopoulos MA
    Am J Hematol; 2021 Sep; 96(9):E321-E324. PubMed ID: 34028867
    [No Abstract]   [Full Text] [Related]  

  • 14. Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner.
    Keeton R; Richardson SI; Moyo-Gwete T; Hermanus T; Tincho MB; Benede N; Manamela NP; Baguma R; Makhado Z; Ngomti A; Motlou T; Mennen M; Chinhoyi L; Skelem S; Maboreke H; Doolabh D; Iranzadeh A; Otter AD; Brooks T; Noursadeghi M; Moon JC; Grifoni A; Weiskopf D; Sette A; Blackburn J; Hsiao NY; Williamson C; Riou C; Goga A; Garrett N; Bekker LG; Gray G; Ntusi NAB; Moore PL; Burgers WA
    Cell Host Microbe; 2021 Nov; 29(11):1611-1619.e5. PubMed ID: 34688376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines.
    Zhang GF; Meng W; Chen L; Ding L; Feng J; Perez J; Ali A; Sun S; Liu Z; Huang Y; Guo H; Gao SJ
    J Med Virol; 2022 Dec; 94(12):5678-5690. PubMed ID: 35902378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
    Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
    Front Immunol; 2021; 12():793191. PubMed ID: 34975897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination.
    Ali H; Alterki A; Sindhu S; Alahmad B; Hammad M; Al-Sabah S; Alghounaim M; Jamal MH; Aldei A; Mairza MJ; Husain M; Deverajan S; Ahmad R; Cherian P; Alkhairi I; Alkandari A; Abubaker J; Abu-Farha M; Al-Mulla F
    Front Immunol; 2021; 12():752233. PubMed ID: 34899701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants.
    Liu J; Bodnar BH; Padhiar NH; Khan AI; Meng F; Saribas S; Wang P; Wang X; McCluskey E; Shah S; Zhao H; Luo JJ; Hu WH; Ho WZ
    Clin Transl Med; 2021 Dec; 11(12):e644. PubMed ID: 34923762
    [No Abstract]   [Full Text] [Related]  

  • 19. Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection.
    Hyun H; Jang AY; Park H; Heo JY; Seo YB; Nham E; Yoon JG; Seong H; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Seok JH; Kim J; Park MS; Song JY
    Front Immunol; 2023; 14():1131229. PubMed ID: 36960070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients With Autoimmune Thyroiditis Present Similar Immunological Response to COVID-19 BNT162b2 mRNA Vaccine With Healthy Subjects, While Vaccination May Affect Thyroid Function: A Clinical Study.
    Paschou SA; Karalis V; Psaltopoulou T; Vasileiou V; Charitaki I; Bagratuni T; Ktena V; Papandroulaki F; Gumeni S; Kassi GN; Trougakos IP; Terpos E; Dimopoulos MA
    Front Endocrinol (Lausanne); 2022; 13():840668. PubMed ID: 35273575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.